ALB and neuroendocrine carcinoma: Similar to BiTE tarlatamab, HPN328, a CD3 × DLL3 × albumin TriTAC fbAb, also achieved promising clinical efficacy, exhibiting antitumor activity against relapsed/refractory metastatic SCLC (confirmed ORR = 50%), neuroendocrine cancer (NEC, other than prostate neuroendocrine cancer; confirmed ORR = 44%), while achieving linear PK and a median half-life of 71 h [46].